Impact of the Coronavirus Disease 2019 pandemic on neoadjuvant chemotherapy use in patients diagnosed with epithelial type ovarian cancer

• DOI: 10.3389/fonc.2024.1290719
• Publication Date: 2024-03-27T12:12:42Z
• Authors: Amrita Mukherjee; Natalie Shammas; Lanfang Xu; Kimberly L. Canna...; Alec D. Gilfillan; Elizabeth A. Szam...; Matthew Monberg; Melissa Hodeib; Chun R. Chao
• Keywords: Pandemic; Medical record

Introduction The Coronavirus Disease 2019 (COVID-19) pandemic posed critical challenges in providing care to ovarian cancer (OC) patients, including delays OC diagnosis and treatment initiation. To accommodate for surgery, the Society of Gynecologic Oncology (SGO) recommended preferential use neoadjuvant chemotherapy during pandemic. purpose this study was assess association COVID-19 with patients diagnosed OC. Methods This retrospective cohort included stage II-IV epithelial subtype between 01/01/2017-06/30/2021 at Kaiser Permanente Southern California (KPSC), a large integrated healthcare system United States. Ovarian 2017-2020 were identified from KPSC’s Surveillance, Epidemiology, End Results (SEER)-affiliated registry. Patients 2021 electronic medical records (EMR) using ICD-10 codes, followed by chart review validate extract information on histology diagnosis. March 4, 2020 used as cut-off define pre-pandemic periods. completion excluded. Data extracted registry EMR, supplemented review. Modified Poisson regression evaluate use. Of 566 160 (28.3%) period. period slightly younger (mean age 62.7 vs 64.9 years, p=0.07) had higher burden Charlson comorbidities (p=0.05) than No differences time initiation observed Neoadjuvant documented 58.7% compared 47.3% (p=0.01). After adjusting covariates, 29% more likely receive [RR(95%CI): 1.29(1.12-1.49)]. Discussions before Future research patient outcomes trends post-pandemic are warranted.